Forcyte Biotechnologies, Inc

the function-first biology company

Forcyte awarded NIH Funding for a FLECS-based migraine model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on vasodilation triggers of migraine pain that will enable rapid phenotypic screening for cranial vasoprotectors.

Scroll to Top